Sells bioprocessing tools and consumables (filtration, chromatography) used to manufacture biologic drugs.
Sells bioprocessing tools and consumables (filtration, chromatography) used to manufacture biologic drugs.
Sells consumables and equipment that customers reorder every time they make a batch of a drug, so revenue rises when a drug that specifies its parts reaches higher volumes. Growth has come largely through buying other makers of filtration and chromatography components.
Moat: narrow (switching costs, process know-how, customer qualification). Once qualified into a customer's biologics manufacturing process, switching suppliers requires costly re-validation.
Headquarters: Waltham, Massachusetts, United States · Founded: 1981 · Employees: 2,000
Size Repligen (RGEN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $11.0B, the 727th largest of 3,085 United States companies the cockpit tracks. Shares closed at $172.67 on 18 Nov 2026.
Performance Over six months the shares gained 54.5%, against +5.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 13.8% over the last twelve months (peer median +14.5%); the operating margin is 8.6% (peer median 19.6%).
Valuation It trades at 71.0× forward earnings against a peer median of 32.0× (5th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.5 points below its cost of capital (10.3% WACC).
Credit Repligen has 1 bond outstanding ($143M).
Short interest Short interest is 11.0% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $806M | $738M | $634M | $632M | $802M |
| Revenue growth | — | +16% | 0% | -21% | — |
| Gross profit | $394M | $351M | $284M | $277M | $429M |
| EBITDA | $167M | $158M | $109M | $135M | $253M |
| Net income | -$11.8M | $48.9M | -$25.5M | $35.6M | $186M |
| Free cash flow | $105M | $91.7M | $145M | $74.9M | $38.7M |
| Capital expenditure | $24.6M | $25.7M | $32.9M | $39.0M | $133M |
| Total debt | $692M | $690M | $686M | $712M | $423M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Repligen RGEN | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% |
| Sartorius Stedim Biotech DIM.PA | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RGEN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | +7.6% | 5th lowest of 21 |
| 6-month return | +54.5% | +5.0% | 4th highest of 21 |
| Distance from 52-week high | -13.2% | -9.7% | 9th lowest of 21 |
| Revenue growth (TTM) | +13.8% | +14.5% | 10th lowest of 20 |
| Operating margin | 8.6% | 19.6% | 6th lowest of 19 |
| Forward P/E | 71.0× | 32.0× | 5th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 56.9% | 17.5% | most demanding of 14 |
| Growth delivered (Del g) | +15.0% | +9.3% | 4th highest of 14 |
| Hurdle (Req g minus delivered) | +41.8 pp | -11.0 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -7.5 pp | +1.4 pp | 5th lowest of 19 |
| EV / EBITDA | 65.1× | 18.2× | most expensive of 12 |
| Net debt / EBITDA | -1.0× | 0.6× | 3rd least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 6.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
Repligen has 1 bond outstanding with $143M face value.